Skip to main content
Medical information Clinical review pending

Cytogenetics

Immunophenotyping by Flow Cytometry CD20 Test

The Immunophenotyping by Flow Cytometry CD20 Test helps diagnose and monitor certain B-cell cancers by detecting the CD20 antigen on B-cells. This test aids doctors in making informed treatment decisions.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
3 mL (2 mL minimum) whole blood in a Lavender Top (EDTA) tube and 3 mL (2 mL minimum) whole blood in a Green Top (Sodium Heparin) tube. Alternatively, 2 mL (1 mL minimum) of bone marrow in a Green Top (Sodium Heparin) tube.
Results
Confirm with the laboratory before booking.
Preparation
No special preparation is required for this blood test. Confirm with the laboratory before booking.
Test priceKSh 7,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the Immunophenotyping by Flow Cytometry CD20 Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Diagnosis of suspected B-cell malignancies
  • ✓Monitoring known B-cell lymphomas or leukemias
  • ✓Assessing response to therapy
  • ✓Characterizing abnormal B-cell populations
  • ✓Evaluating unexplained lymphocytosis
02

In plain language

What this test helps you understand

This test is used to identify and characterize B-cell populations, specifically looking for the presence of the CD20 antigen. It is crucial for the diagnosis, classification, and monitoring of B-cell lymphomas and leukemias.
The Immunophenotyping by Flow Cytometry CD20 Test is a vital diagnostic tool used primarily in the field of oncology. This test is designed to detect the presence of the CD20 antigen on B-cells, which is crucial for diagnosing and monitoring various types of cancers, particularly B-cell malignancies such as Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia. Understanding the expression of CD20 can significantly influence treatment decisions, making this test an important component of cancer care.

This test measures the expression of the CD20 protein on the surface of B-cells. Flow cytometry provides precise quantification and characterization of these cells, allowing healthcare providers to assess the extent of malignancy and tailor treatment strategies accordingly.

Individuals who exhibit symptoms such as swollen lymph nodes, unexplained fatigue, or recurrent infections, or those with a family history of B-cell malignancies should consider undergoing this test. Additionally, patients already diagnosed with certain cancers may require this test for monitoring disease progression or response to treatment.

Benefits of Taking the Test: - Accurate diagnosis of B-cell malignancies. - Guides treatment options based on the expression of CD20. - Helps monitor disease progression and treatment efficacy. - Non-invasive and quick sample collection.

Results from the Immunophenotyping by Flow Cytometry CD20 Test will indicate the percentage of B-cells expressing the CD20 antigen. A higher percentage may suggest a more aggressive form of cancer, while lower levels could indicate a less aggressive disease. It is essential to discuss your results with your oncologist or hematologist to understand their implications fully.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo special preparation is required for this blood test. Confirm with the laboratory before booking.
Sample3 mL (2 mL minimum) whole blood in a Lavender Top (EDTA) tube and 3 mL (2 mL minimum) whole blood in a Green Top (Sodium Heparin) tube. Alternatively, 2 mL (1 mL minimum) of bone marrow in a Green Top (Sodium Heparin) tube.
MethodologyFlow Cytometry
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test detects the presence of CD20 on B-cells but does not provide a definitive diagnosis on its own. Results must be interpreted in conjunction with clinical findings and other laboratory tests. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

CD20 is a protein found on the surface of B-cells, a type of white blood cell. It is not typically found on other cell types.
Many B-cell cancers, like certain lymphomas and leukemias, express CD20. Detecting CD20 helps identify these cancers and can guide treatment decisions.
A blood sample or a bone marrow sample is required. Specific tube types (EDTA and Sodium Heparin) are necessary.
Samples should be shipped immediately at 18°C to 22°C and must not be refrigerated or frozen.
Turnaround time varies. Please contact the laboratory for specific details.
Results indicate the percentage of B-cells expressing CD20. Your doctor will interpret these results in the context of your overall health and other tests.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp